BC
EIGR

Broadfin Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Broadfin Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$18.4M Sell
41,212
-4,367
-10% -$1.55M 2.47% 11
2019
Q3 		$14M Sell
45,579
-9,626
-17% -$3.13M 2.59% 10
2019
Q2 		$17.6M Buy
55,205
+48,762
+757% +$16.9M 3.82% 9
2019
Q1 		$2.7M Buy
6,443
+1,666
+35% +$669K 0.56% 38
2018
Q4 		$1.46M Buy
+4,777
New +$1.54M 0.19% 47

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's EIGR Position: Q4 2019 in Review

Broadfin Capital reduced its Eiger BioPharmaceuticals, Inc. (EIGR) stake by 9.6% in Q4 2019, selling an estimated $1.55M and leaving 41,212 shares worth $18.4M. The position accounts for 2.47% of the portfolio, ranked #11.

Broadfin Capital first reported a position in EIGR in Q4 2018 and has held it in 5 quarters since. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2019.

  • Broadfin Capital held 41,212 shares of Eiger BioPharmaceuticals, Inc. worth $18.4M as of Q4 2019.
  • Broadfin Capital sold 4,367 Eiger BioPharmaceuticals, Inc. shares in Q4 2019, an estimated $1.55M.
  • Eiger BioPharmaceuticals, Inc. made up 2.47% of Broadfin Capital's portfolio in Q4 2019, its #11 holding.
  • Broadfin Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and has held it in 5 quarters since.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.